Nevertheless, since several derivatives of orexins with high affinity and activity to their receptors can bypass the blood–brain barrier, some antagonists have already been approved by the FDA for the treatment of insomnia, and other antagonists and agonists are under investigation for the treatment of various disorders of food intake and behavior [113,271,276]. This evidence concerns the gene HCRT and insomnia measurement.